Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EPS (Weighted Average and Diluted) (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.4 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 8.11% to -$0.4 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.31, a 83.24% increase, with the full-year FY2024 number at -$1.61, up 30.0% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.4 for Q3 2025 at Century Therapeutics, down from -$0.38 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.89 in Q1 2025 to a low of -$1.24 in Q4 2022.
  • A 4-year average of -$0.45 and a median of -$0.53 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 297.78% in 2025; the steepest drop was 8.11% in 2025.
  • Century Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.24 in 2022, then surged by 46.77% to -$0.66 in 2023, then skyrocketed by 36.36% to -$0.42 in 2024, then grew by 4.76% to -$0.4 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's EPS (Weighted Average and Diluted) are -$0.4 (Q3 2025), -$0.38 (Q2 2025), and $0.89 (Q1 2025).